The pharmaceutical company PJSC Borshchagivsky Chemical and Pharmaceutical Plant (BCHF) has changed the composition of its supervisory board.
As reported by the company in the information disclosure system of the National Securities and Stock Market Commission, in accordance with the decision of the annual general meeting on April 30, the shareholders re-elected three ultimate beneficial owners to the supervisory board: Mykola Bezpalka (owns 0.028982% of the authorized capital), Tetyana Artemenko (owns 0.038643% of the share capital), and Oleg Goloborodko (owns 0.038643% of the share capital).
By decision of the meeting, Lyudmila Bezpalko (who owns 1.410491% of the authorized capital) and a representative of the shareholder of PJSC “Farfirma ‘DARNITSA,’ Director of Corporate, Legal Relations and Compliance of ‘Darnitsa’ Sergey Bobylev, were also included in the Supervisory Board.
In addition, the shareholders’ meeting terminated the powers of Supervisory Board member Dmytro Guz.
As reported, BHFZ increased its net profit by almost 17% in 2024 compared to 2023, to UAH 273.402 million. In 2023, BHFZ’s net profit increased by 3.38% compared to 2022, to UAH 262.863 million.
As of the first quarter of 2023, 31.8% of BHFZ shares belonged to the pharmaceutical company PJSC “Pharmaceutical Firm ‘Darnitsa’ (Kyiv). The company’s shareholders also included ‘Beldor Group’ (21.26%) and ‘Lenik Group’ (20.32%).
According to data from the OpenDataBot system, the ultimate beneficiaries of BHFZ are the beneficiaries of the pharmaceutical company Darnitsa, Gleb Zagoriy, Yevgen Sova, Tetiana Artemenko, Mykola Bezpalko, and Oleg Goloborodko.
